Allogeneic iPSC-derived Anti-MICA/B CAR/CD16/IL-15RF-expressing CD38-eliminated NK Cells FT536 clinical trials
Also written FT536.
How each study uses Allogeneic iPSC-derived Anti-MICA/B CAR/CD16/IL-15RF-expressing CD38-eliminated NK Cells FT536 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Allogeneic iPSC-derived Anti-MICA/B CAR/CD16/IL-15RF-expressing CD38-eliminated NK Cells FT536 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- FT536
- 3
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Masonic Cancer Center, University of Minnesota (2) · Fate Therapeutics (1)
Studies
Open first, then newest update. How each study uses Allogeneic iPSC-derived Anti-MICA/B CAR/CD16/IL-15RF-expressing CD38-eliminated NK Cells FT536 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 AstrocytomaRecruitingPhase 1Masonic Cancer Center, University of MinnesotaNCT07560865Written as FT536
- Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerActive, not recruitingPhase 1Masonic Cancer Center, University of MinnesotaNCT06342986Written as FT536
- FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsTerminatedPhase 1Fate TherapeuticsNCT05395052Written as FT536